C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab

Ahmad Y. Abuhelwa, Joaquim Bellmunt, Ganessan Kichenadasse, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich, Ashley M. Hopkins

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)
97 Downloads (Pure)

Fingerprint

Dive into the research topics of 'C-reactive protein provides superior prognostic accuracy than the IMDC risk model in renal cell carcinoma treated with Atezolizumab/Bevacizumab'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology